Affordable Access

Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis

Authors
  • Bachert, Claus;
  • Hellings, Peter W; 9634;
  • Mullol, Joaquim;
  • Hamilos, Daniel L;
  • Gevaert, Philippe;
  • Naclerio, Robert M;
  • Joish, Vijay N;
  • Chao, Jingdong;
  • Mannent, Leda P;
  • Amin, Nikhil;
  • Abbe, Adeline;
  • Taniou, Christine;
  • Fan, Chunpeng;
  • Pirozzi, Gianluca;
  • Graham, Neil MH;
  • Mahajan, Puneet;
  • Staudinger, Heribert;
  • Khan, Asif;
Publication Date
Oct 23, 2019
Source
Lirias
Keywords
License
Unknown
External links

Abstract

BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) negatively affects health-related quality of life (HRQoL). In a previously reported randomized clinical trial (NCT01920893), addition of dupilumab to mometasone furoate in patients with CRSwNP refractory to intranasal corticosteroids (INCS) significantly improved endoscopic, radiographic, and clinical endpoints and patient-reported outcomes. The objective of this analysis was to examine the impact of dupilumab treatment on HRQoL and productivity using secondary outcome data from this trial. METHODS: Following a 4-week mometasone furoate nasal spray run-in, patients were randomized to commence subcutaneous dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks [n = 30], or matched placebo [n = 30]). Outcomes included scores on the CRS disease severity visual analog scale (VAS), 22-item Sino-Nasal Outcome Test (SNOT-22), 5-dimension EuroQoL (EQ-5D) general health status VAS, and 36-item Short-Form Health Survey (SF-36) for HRQoL and nasal polyp-related healthcare resource use questionnaires. RESULTS: Following 16 weeks of treatment, the proportion of patients with moderate-to-severe CRSwNP (VAS > 3-10) decreased from 86.2% to 21.4% with dupilumab and 88.0% to 84.2% with placebo. Dupilumab (vs placebo) resulted in significantly greater improvement in HRQoL, based on SNOT-22, SF-36, and EQ-5D VAS scores. The dupilumab group had a significantly lower adjusted annualized mean number of sick leave days (0.09, vs 4.18 with placebo, P = .015) and significantly greater improvement (vs placebo) in the SNOT-22 item "reduced productivity." CONCLUSIONS: In adults with CRSwNP refractory to treatment with INCS alone, the addition of dupilumab reduced disease severity, significantly improved HRQoL, and improved productivity. / status: published

Report this publication

Statistics

Seen <100 times